NICE CG184: Dyspepsia and gastro‑oesophageal reflux disease: Investigation and management of dyspepsia, symptoms suggestive of gastro‑oesophageal reflux disease, or both
NICE CG61: Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care
Asacol
Tablets - 400mg, 800mg
Enema - 1g
Suppositories - 500mg
Pentasa
Tablets - 500mg
Enema - 1g
Suppositories - 1g
Mezavant XL
Tablets - 1.2g
The delivery mechanisms of oral mesalazine may vary. These preparations should not be considered interchangeable.
Film Coated Tablets - 12.5mg & 25mg
Recommended by NICE for treating opioid induced constipation in adults whose constipation has not adequately responded to laxatives. An inadequate response is defined as opioid‑induced constipation symptoms of at least moderate severity in at least 1 of the 4 stool symptom domains (that is, incomplete bowel movement, hard stools, straining or false alarms) while taking at least 1 laxative class for at least 4 days during the prior 2 weeks
Tablets - 1mg, 2mg
Recommended by NICE for treatment of chronic constipation in women for whom treatment with at least 2 laxatives from different classes, at highest tolerated recommended doses for at least 6 months, has failed and invasive treatment is being considered. Initiated only by clinicians experienced in treatment of chronic constipation. Should be reviewed if not effective after 4 weeks.
Capsules - 24microgram
Recommended by NICE for treatment of chronic constipation in Adults for whom treatment with at least 2 laxatives from different classes, at highest tolerated recommended doses for at least 6 months, has failed and invasive treatment is being considered. Initiated only by clinicians experienced in treatment of chronic constipation. Should be reviewed if not effective after 2 weeks.
Ointment - 0.4%
NICE evidence summary for unlicensed / off-label medicines:
ESUOM7 Chronic anal fissure: 0.2% topical glyceryl trinitrate ointment
Capsules - 60mg, 120mg
Adjunct in obesity (in conjunction with a mildly hypocaloric diet in individuals with a body mass index (BMI) of 30 kg/m2 or more or in individuals with a BMI of 28 kg/m2 or more in the presence of other risk factors such as type 2 diabetes, hypertension, or hypercholesterolaemia)